Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder

Rongrong Tao, Graham J. Emslie, Taryn L. Mayes, Paul A. Nakonezny, Betsy D. Kennard

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: Knowing the timing of specific depressive symptom improvement will enable clinicians to prepare their patients well and improve treatment outcome, whereas recognizing which depressive symptoms may show delayed improvement will help clinicians to provide additional interventions early in treatment. In a prospective open-label fluoxetine study, we investigated the timing of depressive symptom improvement during acute treatment, and identified common remaining symptoms following 4, 8, and 12 weeks of acute treatment in depressed youths. Method: A total of 168 children and adolescents, aged 7-18 years, with primary diagnoses of major depressive disorder (MDD) received 12 weeks of fluoxetine treatment. Youths were evaluated using the Kiddie Schedule for Affective Disorders and Schizophrenia. The outcome measure included the Children's Depression Rating Scale-Revised. Results: All depressive symptoms improved, particularly during the first 4 weeks of acute treatment. Forty-seven percent of remitters reported at least one residual symptom following 12 weeks, with most common residual symptoms being impaired school performance, insomnia, and irritability. Conclusions: Residual symptoms are common, even among remitters, at the end of 12 weeks of acute treatment. There is a need for clinicians to monitor symptom improvement and potentially provide additional interventions for the more resistant symptoms, such as insomnia and school performance.

Original languageEnglish (US)
Pages (from-to)423-430
Number of pages8
JournalJournal of Child and Adolescent Psychopharmacology
Volume20
Issue number5
DOIs
StatePublished - Oct 1 2010

Fingerprint

Major Depressive Disorder
Antidepressive Agents
Pediatrics
Depression
Fluoxetine
Sleep Initiation and Maintenance Disorders
Therapeutics
Mood Disorders
Schizophrenia
Appointments and Schedules
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

@article{b9a22b8dc6574266a692fd4e5fd5c2e8,
title = "Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder",
abstract = "Objective: Knowing the timing of specific depressive symptom improvement will enable clinicians to prepare their patients well and improve treatment outcome, whereas recognizing which depressive symptoms may show delayed improvement will help clinicians to provide additional interventions early in treatment. In a prospective open-label fluoxetine study, we investigated the timing of depressive symptom improvement during acute treatment, and identified common remaining symptoms following 4, 8, and 12 weeks of acute treatment in depressed youths. Method: A total of 168 children and adolescents, aged 7-18 years, with primary diagnoses of major depressive disorder (MDD) received 12 weeks of fluoxetine treatment. Youths were evaluated using the Kiddie Schedule for Affective Disorders and Schizophrenia. The outcome measure included the Children's Depression Rating Scale-Revised. Results: All depressive symptoms improved, particularly during the first 4 weeks of acute treatment. Forty-seven percent of remitters reported at least one residual symptom following 12 weeks, with most common residual symptoms being impaired school performance, insomnia, and irritability. Conclusions: Residual symptoms are common, even among remitters, at the end of 12 weeks of acute treatment. There is a need for clinicians to monitor symptom improvement and potentially provide additional interventions for the more resistant symptoms, such as insomnia and school performance.",
author = "Rongrong Tao and Emslie, {Graham J.} and Mayes, {Taryn L.} and Nakonezny, {Paul A.} and Kennard, {Betsy D.}",
year = "2010",
month = "10",
day = "1",
doi = "10.1089/cap.2009.0116",
language = "English (US)",
volume = "20",
pages = "423--430",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder

AU - Tao, Rongrong

AU - Emslie, Graham J.

AU - Mayes, Taryn L.

AU - Nakonezny, Paul A.

AU - Kennard, Betsy D.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Objective: Knowing the timing of specific depressive symptom improvement will enable clinicians to prepare their patients well and improve treatment outcome, whereas recognizing which depressive symptoms may show delayed improvement will help clinicians to provide additional interventions early in treatment. In a prospective open-label fluoxetine study, we investigated the timing of depressive symptom improvement during acute treatment, and identified common remaining symptoms following 4, 8, and 12 weeks of acute treatment in depressed youths. Method: A total of 168 children and adolescents, aged 7-18 years, with primary diagnoses of major depressive disorder (MDD) received 12 weeks of fluoxetine treatment. Youths were evaluated using the Kiddie Schedule for Affective Disorders and Schizophrenia. The outcome measure included the Children's Depression Rating Scale-Revised. Results: All depressive symptoms improved, particularly during the first 4 weeks of acute treatment. Forty-seven percent of remitters reported at least one residual symptom following 12 weeks, with most common residual symptoms being impaired school performance, insomnia, and irritability. Conclusions: Residual symptoms are common, even among remitters, at the end of 12 weeks of acute treatment. There is a need for clinicians to monitor symptom improvement and potentially provide additional interventions for the more resistant symptoms, such as insomnia and school performance.

AB - Objective: Knowing the timing of specific depressive symptom improvement will enable clinicians to prepare their patients well and improve treatment outcome, whereas recognizing which depressive symptoms may show delayed improvement will help clinicians to provide additional interventions early in treatment. In a prospective open-label fluoxetine study, we investigated the timing of depressive symptom improvement during acute treatment, and identified common remaining symptoms following 4, 8, and 12 weeks of acute treatment in depressed youths. Method: A total of 168 children and adolescents, aged 7-18 years, with primary diagnoses of major depressive disorder (MDD) received 12 weeks of fluoxetine treatment. Youths were evaluated using the Kiddie Schedule for Affective Disorders and Schizophrenia. The outcome measure included the Children's Depression Rating Scale-Revised. Results: All depressive symptoms improved, particularly during the first 4 weeks of acute treatment. Forty-seven percent of remitters reported at least one residual symptom following 12 weeks, with most common residual symptoms being impaired school performance, insomnia, and irritability. Conclusions: Residual symptoms are common, even among remitters, at the end of 12 weeks of acute treatment. There is a need for clinicians to monitor symptom improvement and potentially provide additional interventions for the more resistant symptoms, such as insomnia and school performance.

UR - http://www.scopus.com/inward/record.url?scp=77958577384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958577384&partnerID=8YFLogxK

U2 - 10.1089/cap.2009.0116

DO - 10.1089/cap.2009.0116

M3 - Article

VL - 20

SP - 423

EP - 430

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 5

ER -